Physician profile
Andrew Lee
NPI 1619904216
$3,976.63
in general payments reported to CMS, 2019-2025
23 companies · $604 in 2025
The $604 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $705 · 2020: $281 · 2021: $525 · 2022: $583 · 2023: $566 · 2024: $713 · 2025: $604.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,883.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,882.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $721.08 | 2019-2025 | Biktarvy |
| Merck Sharp & Dohme LLC | $647.15 | 2019-2025 | Dificid, Zerbaxa, Pifeltro |
| Viiv Healthcare Company | $552.60 | 2019-2025 | Dovato, Cabenuva, Apretude |
| Insmed, INC. | $325.24 | 2019-2025 | Arikayce |
| Abbvie INC. | $286.73 | 2021-2025 | |
| Paratek Pharmaceuticals, INC. | $238.03 | 2021-2025 | Nuzyra |
| Aimmune Therapeutics, INC. | $222.46 | 2024-2025 | Vowst |
| Glaxosmithkline, LLC. | $211.60 | 2019-2022 | |
| Melinta Therapeutics, LLC | $184.13 | 2019-2025 | Rezzayo, Kimyrsa, Orbactiv |
| Smith+Nephew, INC. | $111.29 | 2019 | |
| Janssen Biotech, INC. | $77.63 | 2022-2023 | Symtuza |
| Theratechnologies INC. | $73.43 | 2023-2025 | Trogarzo, Egrifta |
| Ferring Pharmaceuticals INC. | $69.07 | 2022-2024 | Rebyota |
| Astellas Pharma US INC | $46.98 | 2019-2024 | Cresemba |
| Grifols USA, LLC | $46.77 | 2019-2020 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Napo Pharmaceuticals INC | $33.72 | 2024-2025 | Mytesi |
| Emd Serono, INC. | $31.17 | 2025 | |
| Shionogi INC | $18.74 | 2022 | |
| Pfizer INC. | $18.05 | 2025 | |
| Lilly USA, LLC | $16.39 | 2025 | Zepbound |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.67 | 2023 | |
| Nabriva Therapeutics, Plc | $14.98 | 2021 | |
| Vyera Pharmaceuticals, LLC | $13.72 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.